Being overweight raises your risk of thyroid cancer ... One study reported that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%. As of now, the FDA warning ...

The following text highlights some of these precautions. Boxed warning: Risk of thyroid cancer Semaglutide (the active ingredient in Ozempic and Wegovy) has a boxed warning for a possible risk of ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

However, semaglutide was not linked to a significantly reduced risk of developing thyroid, stomach, or breast cancer. Yoni Resnick, PharmD, the director of pharmacy clinical services with New ...

A recent survey reveals the foods that people are less likely to eat once they start taking GLP-1 medications like Ozempic.

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...

Semaglutide was also found to lower blood ... but the label indicates thyroid cancer risk. Contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or multiple ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

which investigated more than 16,000 patients over a period of six years, raised ocular safety issues related to semaglutide. The study found that the medicine can potentially increase the risk of ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date.